Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | GPR4 | P46093 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5560225 | 0.97 | SMN1; SMN2 (0.45) | SMN1; SMN2USP2CHRM2CHRM4CHRM1 | |
| SCHEMBL25905171 | 0.96 | SMN1; SMN2 (0.44) | SMN1; SMN2USP2CHRM2CHRM4CHRM1 | |
| SCHEMBL15435945 | 0.96 | SMN1; SMN2 (0.44) | SMN1; SMN2USP2CHRM2CHRM4CHRM1 | |
| SCHEMBL39756 | 0.89 | USP2 (0.51) | SMN1; SMN2USP2CHRM2CHRM4CHRM1 | |
| SCHEMBL23251655 | 0.87 | USP2 (0.46) | SMN1; SMN2USP2CHRM2CHRM4CHRM1 | |
| SCHEMBL27097884 | 0.86 | EPHX2 (0.44) | SMN1; SMN2USP2CHRM2CHRM4CHRM1 | |
| SCHEMBL25678453 | 0.85 | HPGD (0.49) | SMN1; SMN2USP2CHRM2CHRM4CHRM1 | |
| SCHEMBL15352136 | 0.84 | USP2 (0.44) | SMN1; SMN2USP2CHRM2CHRM4CHRM1 | |
| SCHEMBL22123127 | 0.84 | USP2 (0.44) | SMN1; SMN2USP2CHRM2CHRM4CHRM1 | |
| SCHEMBL22262696 | 0.84 | USP2 (0.44) | SMN1; SMN2USP2CHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569937-B1 | C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES | BRISTOL MYERS SQUIBB CO (US) | 2011-11-23 | — | — | EP | disclosed |
| US-7148220-B2 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-12 | — | — | US | disclosed |
| US-20040142931-A1 | C-6 modified indazolylpyrrolotriazines | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142931-A1 | C-6 modified indazolylpyrrolotriazines | ERBB2, ERBB4, EGFR | SMN1; SMN2 4567/4885USP2 4320/4885CHRM2 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.